Indication
Hetlioz is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults.
Loading your page…
Loading your page…
Sleep Disorders, Circadian Rhythm
Marketing Authorisation Holder: Vanda Pharmaceuticals Netherlands B.V.
EMA Authorisation: 03/07/2015
INN: tasimelteon
AI Drug & Interaction Analysis
Free account required
Ask Osler about Hetlioz: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.